JP2015502365A5 - - Google Patents

Info

Publication number

JP2015502365A5

JP2015502365A5 JP2014547389A JP2014547389A JP2015502365A5 JP 2015502365 A5 JP2015502365 A5 JP 2015502365A5 JP 2014547389 A JP2014547389 A JP 2014547389A JP 2014547389 A JP2014547389 A JP 2014547389A JP 2015502365 A5 JP2015502365 A5 JP 2015502365A5

Authority

JP

Japan

Prior art keywords

diseases

disorders

oligonucleotide

composition

disease

Prior art date

2012-12-12

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
• 108091034117 Oligonucleotide Proteins 0.000 claims description 16
• 201000010099 disease Diseases 0.000 claims description 13
• 208000035475 disorder Diseases 0.000 claims description 13
• 230000001225 therapeutic effect Effects 0.000 claims description 13
• 239000000074 antisense oligonucleotide Substances 0.000 claims description 4
• 238000012230 antisense oligonucleotides Methods 0.000 claims description 4
• 230000014509 gene expression Effects 0.000 claims description 3
• 230000009368 gene silencing by RNA Effects 0.000 claims description 3
• 238000001727 in vivo Methods 0.000 claims description 2
• 238000012986 modification Methods 0.000 claims description 2
• 230000004048 modification Effects 0.000 claims description 2
• 150000007523 nucleic acids Chemical group 0.000 claims 10
• 108020004707 nucleic acids Proteins 0.000 claims 9
• 102000039446 nucleic acids Human genes 0.000 claims 9
• 239000002679 microRNA Substances 0.000 claims 7
• 239000002773 nucleotide Substances 0.000 claims 7
• 125000003729 nucleotide group Chemical group 0.000 claims 7
• 102000004169 proteins and genes Human genes 0.000 claims 7
• 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 5
• 239000000758 substrate Substances 0.000 claims 5
• 208000024172 Cardiovascular disease Diseases 0.000 claims 4
• 208000012902 Nervous system disease Diseases 0.000 claims 4
• 208000025966 Neurological disease Diseases 0.000 claims 4
• 108091005461 Nucleic proteins Proteins 0.000 claims 4
• 230000002159 abnormal effect Effects 0.000 claims 4
• 208000026278 immune system disease Diseases 0.000 claims 4
• 208000027866 inflammatory disease Diseases 0.000 claims 4
• 108020004999 messenger RNA Proteins 0.000 claims 4
• 208000030159 metabolic disease Diseases 0.000 claims 4
• 230000002018 overexpression Effects 0.000 claims 4
• 230000009452 underexpressoin Effects 0.000 claims 4
• 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 claims 3
• 108091070501 miRNA Proteins 0.000 claims 3
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 3
• 108090000623 proteins and genes Proteins 0.000 claims 3
• 208000035473 Communicable disease Diseases 0.000 claims 2
• 108020004414 DNA Proteins 0.000 claims 2
• 206010028980 Neoplasm Diseases 0.000 claims 2
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 2
• 108091027967 Small hairpin RNA Proteins 0.000 claims 2
• 108020004459 Small interfering RNA Proteins 0.000 claims 2
• 201000011510 cancer Diseases 0.000 claims 2
• 208000030533 eye disease Diseases 0.000 claims 2
• 230000002062 proliferating effect Effects 0.000 claims 2
• 208000017520 skin disease Diseases 0.000 claims 2
• 239000004055 small Interfering RNA Substances 0.000 claims 2
• 108091023037 Aptamer Proteins 0.000 claims 1
• 108091026898 Leader sequence (mRNA) Proteins 0.000 claims 1
• 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
• 108091081024 Start codon Proteins 0.000 claims 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 1
• 108091036066 Three prime untranslated region Proteins 0.000 claims 1
• 230000000692 anti-sense effect Effects 0.000 claims 1
• 230000033228 biological regulation Effects 0.000 claims 1
• 229910052799 carbon Inorganic materials 0.000 claims 1
• 125000004432 carbon atom Chemical group C* 0.000 claims 1
• 230000000295 complement effect Effects 0.000 claims 1
• NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 claims 1
• 230000001939 inductive effect Effects 0.000 claims 1
• 238000000034 method Methods 0.000 claims 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
• 230000003278 mimic effect Effects 0.000 claims 1
• 239000002777 nucleoside Substances 0.000 claims 1
• 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
• 125000003835 nucleoside group Chemical class 0.000 claims 1
• 125000004430 oxygen atom Chemical group O* 0.000 claims 1
• 150000008039 phosphoramides Chemical class 0.000 claims 1
• 108091007428 primary miRNA Proteins 0.000 claims 1
• 239000002924 silencing RNA Substances 0.000 claims 1
• 210000004027 cell Anatomy 0.000 description 2
• 150000001875 compounds Chemical class 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
• 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 1
• 108091030071 RNAI Proteins 0.000 description 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 238000002716 delivery method Methods 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• 230000012202 endocytosis Effects 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 210000003093 intracellular space Anatomy 0.000 description 1
• 210000003712 lysosome Anatomy 0.000 description 1
• 230000001868 lysosomic effect Effects 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000009919 sequestration Effects 0.000 description 1